Abstract 1205P
Background
The probability of discovering mutation-based therapy through comprehensive genomic profiling (CGP) remains low. To enhance the effectiveness and efficiency of precision medicine, it is crucial to identify patients who are likely to benefit from CGP tests. This study aimed to identify characteristics of patients in which mutation-based treatments are discovered by CGP tests.
Methods
We retrospectively analyzed data from 60,655 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which covers 99.7% of cancer patients who have undergone CGP tests in Japan. We developed an eXtreme Gradient Boosting (XGBoost) machine learning model, and used clinical information as input to predict the likelihood of discovering mutation-based drugs through CGP tests. SHapley Additive exPlanations (SHAP) was employed to extract significant features contributing to the model prediction.
Results
The prediction model achieved an area under the receiver operating characteristic curve of 0.819 for the overall cancer population. Positive SHAP values were observed for patients with breast (mean SHAP in breast cancer patients: 1.66), lung (1.19), prostate (0.81), and colorectal (0.17) cancers, while negative SHAP values were associated with pancreatic (-2.40), brain (-1.37), and biliary tract (-0.44) cancers. Positive SHAP values were also associated with the presence of distant metastases and advanced age. Similar trends were observed in cancer type-specific prediction models. Distant metastasis was also associated with discovery of mutation-based therapy in the breast cancer-specific model, even after excluding liquid CGP data. In the adolescent and young adult (AYA) group, brain and bone tumors were associated with negative SHAP values.
Conclusions
Our analysis identified features that predict cases in which mutation-based treatments are discovered by CGP tests, both in the overall cancer population and within specific cancer types and the AYA group. Expedited CGP testing is recommended for patients who match the identified profile to facilitate early targeted therapy interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Watanabe, H. Kage: Financial Interests, Institutional, Research Funding: Konica Minolta. K. Oda: Financial Interests, Personal, Advisory Role: Chugai Pharma, Takeda, AstraZeneca/Merck, AstraZeneca, Konica Minolta; Financial Interests, Institutional, Research Funding: AstraZeneca/Merck, Konica Minolta. All other authors have declared no conflicts of interest.
Resources from the same session
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10